FI111161B - Menetelmä kemoherkistävinä aineina käyttökelpoisten 10,11-metanodibentsosuberaanijohdannaisten valmistamiseksi - Google Patents

Menetelmä kemoherkistävinä aineina käyttökelpoisten 10,11-metanodibentsosuberaanijohdannaisten valmistamiseksi Download PDF

Info

Publication number: FI111161B
Authority: FI; Finland
Prior art keywords: formula; compound; compounds; pharmaceutically acceptable; acid
Prior art date: 1993-04-19

Application number

FI954979A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI954979A7 (fi

FI954979A0 (fi

Inventor

Jurg Roland Pfister

Doris Lynne Slate

Original Assignee

Syntex Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-04-19

Filing date

1995-10-18

Publication date

2003-06-13

1995-10-18 Application filed by Syntex Inc filed Critical Syntex Inc

1995-10-18 Publication of FI954979A7 publication Critical patent/FI954979A7/fi

1995-10-18 Publication of FI954979A0 publication Critical patent/FI954979A0/fi

2003-06-13 Application granted granted Critical

2003-06-13 Publication of FI111161B publication Critical patent/FI111161B/fi

Links

238000000034 method Methods 0.000 title claims description 36
238000002360 preparation method Methods 0.000 title claims description 33
230000008569 process Effects 0.000 title claims description 14
230000003034 chemosensitisation Effects 0.000 title abstract description 11
239000006114 chemosensitizer Substances 0.000 title description 5
150000001875 compounds Chemical class 0.000 claims abstract description 149
150000003839 salts Chemical class 0.000 claims abstract description 43
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 12
125000004423 acyloxy group Chemical group 0.000 claims abstract description 11
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 10
229910052801 chlorine Inorganic materials 0.000 claims abstract description 10
229910052731 fluorine Inorganic materials 0.000 claims abstract description 10
229910052794 bromium Inorganic materials 0.000 claims abstract description 9
125000004122 cyclic group Chemical group 0.000 claims abstract description 8
125000001072 heteroaryl group Chemical group 0.000 claims abstract description 6
125000005842 heteroatom Chemical group 0.000 claims abstract description 5
229910052760 oxygen Inorganic materials 0.000 claims abstract description 5
229910052717 sulfur Inorganic materials 0.000 claims abstract description 3
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 78
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 32
-1 5-quinolyl Chemical group 0.000 claims description 30
238000006243 chemical reaction Methods 0.000 claims description 27
SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 23
239000002253 acid Substances 0.000 claims description 22
239000002585 base Substances 0.000 claims description 9
MMRYHBTWIHLITG-UHFFFAOYSA-N 5-(oxiran-2-ylmethoxy)quinoline Chemical compound C=1C=CC2=NC=CC=C2C=1OCC1CO1 MMRYHBTWIHLITG-UHFFFAOYSA-N 0.000 claims description 7
125000000217 alkyl group Chemical group 0.000 claims description 6
239000012458 free base Substances 0.000 claims description 5
125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 claims description 3
150000002118 epoxides Chemical class 0.000 claims description 3
229910052736 halogen Inorganic materials 0.000 claims description 3
125000005843 halogen group Chemical group 0.000 claims description 3
125000005493 quinolyl group Chemical group 0.000 claims description 3
150000001266 acyl halides Chemical class 0.000 claims 1
230000036457 multidrug resistance Effects 0.000 abstract description 13
206010028980 Neoplasm Diseases 0.000 abstract description 12
201000011510 cancer Diseases 0.000 abstract description 10
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 5
238000002512 chemotherapy Methods 0.000 abstract description 4
229910052757 nitrogen Inorganic materials 0.000 abstract description 3
125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 abstract description 2
239000000203 mixture Substances 0.000 description 38
239000000243 solution Substances 0.000 description 32
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 27
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 22
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
239000011541 reaction mixture Substances 0.000 description 14
239000002904 solvent Substances 0.000 description 14
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
239000002246 antineoplastic agent Substances 0.000 description 12
239000003814 drug Substances 0.000 description 12
239000000546 pharmaceutical excipient Substances 0.000 description 12
229940079593 drug Drugs 0.000 description 11
239000000126 substance Substances 0.000 description 11
239000004480 active ingredient Substances 0.000 description 10
230000000694 effects Effects 0.000 description 10
GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 10
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
229940009456 adriamycin Drugs 0.000 description 9
210000004027 cell Anatomy 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
239000000725 suspension Substances 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
241000699670 Mus sp. Species 0.000 description 7
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
239000013543 active substance Substances 0.000 description 7
125000004104 aryloxy group Chemical group 0.000 description 7
238000003556 assay Methods 0.000 description 7
201000010099 disease Diseases 0.000 description 7
238000009472 formulation Methods 0.000 description 7
239000012074 organic phase Substances 0.000 description 7
239000000741 silica gel Substances 0.000 description 7
229910002027 silica gel Inorganic materials 0.000 description 7
239000003826 tablet Substances 0.000 description 7
238000012360 testing method Methods 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
125000003118 aryl group Chemical group 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
230000000973 chemotherapeutic effect Effects 0.000 description 6
239000008101 lactose Substances 0.000 description 6
239000007788 liquid Substances 0.000 description 6
239000000047 product Substances 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
HEKGUAOOPJRMPC-UHFFFAOYSA-N 4-(oxiran-2-ylmethoxy)-2,1,3-benzoxadiazole Chemical compound C=1C=CC2=NON=C2C=1OCC1CO1 HEKGUAOOPJRMPC-UHFFFAOYSA-N 0.000 description 5
241000124008 Mammalia Species 0.000 description 5
150000001450 anions Chemical class 0.000 description 5
229910052799 carbon Inorganic materials 0.000 description 5
239000000460 chlorine Substances 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
125000005553 heteroaryloxy group Chemical group 0.000 description 5
239000001257 hydrogen Substances 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
235000019359 magnesium stearate Nutrition 0.000 description 5
231100000252 nontoxic Toxicity 0.000 description 5
230000003000 nontoxic effect Effects 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
239000000825 pharmaceutical preparation Substances 0.000 description 5
GYESAYHWISMZOK-UHFFFAOYSA-N quinolin-5-ol Chemical compound C1=CC=C2C(O)=CC=CC2=N1 GYESAYHWISMZOK-UHFFFAOYSA-N 0.000 description 5
238000011160 research Methods 0.000 description 5
239000007787 solid Substances 0.000 description 5
JYVBLAKBEMDPBD-UHFFFAOYSA-N 2,1,3-benzoxadiazol-4-ol Chemical compound OC1=CC=CC2=NON=C12 JYVBLAKBEMDPBD-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
229940041181 antineoplastic drug Drugs 0.000 description 4
238000001516 cell proliferation assay Methods 0.000 description 4
125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 4
125000004433 nitrogen atom Chemical group N* 0.000 description 4
239000000843 powder Substances 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
239000011734 sodium Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
125000001424 substituent group Chemical group 0.000 description 4
238000013268 sustained release Methods 0.000 description 4
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
229960004528 vincristine Drugs 0.000 description 4
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 4
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 4
IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 3
MMRYHBTWIHLITG-VIFPVBQESA-N 5-[[(2s)-oxiran-2-yl]methoxy]quinoline Chemical compound C=1C=CC2=NC=CC=C2C=1OC[C@@H]1CO1 MMRYHBTWIHLITG-VIFPVBQESA-N 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
206010059866 Drug resistance Diseases 0.000 description 3
DRNLZGFTDLLKGN-UHFFFAOYSA-M FC(C(=O)O)F.[Cl-].[Na+] Chemical compound FC(C(=O)O)F.[Cl-].[Na+] DRNLZGFTDLLKGN-UHFFFAOYSA-M 0.000 description 3
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000000443 aerosol Substances 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
235000010980 cellulose Nutrition 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000001816 cooling Methods 0.000 description 3
SNVTZAIYUGUKNI-UHFFFAOYSA-N dibenzo[1,2-a:1',2'-e][7]annulen-11-one Chemical compound C1=CC2=CC=CC=C2C(=O)C2=CC=CC=C21 SNVTZAIYUGUKNI-UHFFFAOYSA-N 0.000 description 3
SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
239000011737 fluorine Substances 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
238000002955 isolation Methods 0.000 description 3
201000004792 malaria Diseases 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
239000012299 nitrogen atmosphere Substances 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
230000035515 penetration Effects 0.000 description 3
239000006187 pill Substances 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
238000000926 separation method Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
239000012730 sustained-release form Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
150000003626 triacylglycerols Chemical class 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
MSSDTZLYNMFTKN-UHFFFAOYSA-N 1-Piperazinecarboxaldehyde Chemical compound O=CN1CCNCC1 MSSDTZLYNMFTKN-UHFFFAOYSA-N 0.000 description 2
IBYHHJPAARCAIE-UHFFFAOYSA-N 1-bromo-2-chloroethane Chemical compound ClCCBr IBYHHJPAARCAIE-UHFFFAOYSA-N 0.000 description 2
NIDSRGCVYOEDFW-UHFFFAOYSA-N 1-bromo-4-chlorobutane Chemical compound ClCCCCBr NIDSRGCVYOEDFW-UHFFFAOYSA-N 0.000 description 2
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
NARVIWMVBMUEOG-UHFFFAOYSA-N 2-Hydroxy-propylene Natural products CC(O)=C NARVIWMVBMUEOG-UHFFFAOYSA-N 0.000 description 2
SMKKEOQDQNCTGL-UHFFFAOYSA-N 2-[(2-nitrophenoxy)methyl]oxirane Chemical compound [O-][N+](=O)C1=CC=CC=C1OCC1OC1 SMKKEOQDQNCTGL-UHFFFAOYSA-N 0.000 description 2
DAHPARGKQAOYKA-UHFFFAOYSA-N 2-[[2-(difluoromethoxy)phenoxy]methyl]oxirane Chemical compound FC(F)OC1=CC=CC=C1OCC1OC1 DAHPARGKQAOYKA-UHFFFAOYSA-N 0.000 description 2
XHCSHOXTUANFOG-UHFFFAOYSA-N 3-(oxiran-2-ylmethoxy)pyridine Chemical compound C1OC1COC1=CC=CN=C1 XHCSHOXTUANFOG-UHFFFAOYSA-N 0.000 description 2
GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 2
JLHLCJRXRYOENY-UHFFFAOYSA-N 5-(3-chloropropoxy)quinoline Chemical compound C1=CC=C2C(OCCCCl)=CC=CC2=N1 JLHLCJRXRYOENY-UHFFFAOYSA-N 0.000 description 2
IQFORTVWCXFOPZ-UHFFFAOYSA-N 5-(4-chlorobutoxy)quinoline Chemical compound C1=CC=C2C(OCCCCCl)=CC=CC2=N1 IQFORTVWCXFOPZ-UHFFFAOYSA-N 0.000 description 2
RWIVADKBWOJRFC-UHFFFAOYSA-N 5-[2-(oxiran-2-yl)ethoxy]quinoline Chemical compound C=1C=CC2=NC=CC=C2C=1OCCC1CO1 RWIVADKBWOJRFC-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
229920002785 Croscarmellose sodium Polymers 0.000 description 2
KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
229940122803 Vinca alkaloid Drugs 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
150000001263 acyl chlorides Chemical class 0.000 description 2
125000002947 alkylene group Chemical group 0.000 description 2
IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 2
230000000340 anti-metabolite Effects 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
229940005513 antidepressants Drugs 0.000 description 2
229940100197 antimetabolite Drugs 0.000 description 2
239000002256 antimetabolite Substances 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
230000008499 blood brain barrier function Effects 0.000 description 2
210000001218 blood-brain barrier Anatomy 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
239000003183 carcinogenic agent Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
229960001681 croscarmellose sodium Drugs 0.000 description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
238000002784 cytotoxicity assay Methods 0.000 description 2
231100000263 cytotoxicity test Toxicity 0.000 description 2
238000011161 development Methods 0.000 description 2
PJQCANLCUDUPRF-UHFFFAOYSA-N dibenzocycloheptene Chemical compound C1CC2=CC=CC=C2CC2=CC=CC=C12 PJQCANLCUDUPRF-UHFFFAOYSA-N 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
229960004679 doxorubicin Drugs 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
229960005420 etoposide Drugs 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000003818 flash chromatography Methods 0.000 description 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
239000001530 fumaric acid Substances 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000008103 glucose Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
VHFUHRXYRYWELT-UHFFFAOYSA-N methyl 2,2,2-trichloroacetate Chemical compound COC(=O)C(Cl)(Cl)Cl VHFUHRXYRYWELT-UHFFFAOYSA-N 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
239000003607 modifier Substances 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
239000006179 pH buffering agent Substances 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
239000012071 phase Substances 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
239000001294 propane Substances 0.000 description 2
238000000746 purification Methods 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
150000003248 quinolines Chemical class 0.000 description 2
230000035484 reaction time Effects 0.000 description 2
239000010454 slate Substances 0.000 description 2
239000012279 sodium borohydride Substances 0.000 description 2
229910000033 sodium borohydride Inorganic materials 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
229960001278 teniposide Drugs 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
NYBWUHOMYZZKOR-UHFFFAOYSA-N tes-adt Chemical class C1=C2C(C#C[Si](CC)(CC)CC)=C(C=C3C(SC=C3)=C3)C3=C(C#C[Si](CC)(CC)CC)C2=CC2=C1SC=C2 NYBWUHOMYZZKOR-UHFFFAOYSA-N 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
229960001722 verapamil Drugs 0.000 description 2
229960003048 vinblastine Drugs 0.000 description 2
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
NAWYNBMEGSHUAY-SECBINFHSA-N (2R)-1-quinolin-5-yloxypropan-2-ol Chemical compound N1=CC=CC2=C(C=CC=C12)OC[C@@H](C)O NAWYNBMEGSHUAY-SECBINFHSA-N 0.000 description 1
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
ZGMJYTYLTJFNCS-VQYXCCSOSA-N (e)-but-2-enedioic acid;1-[4-(2-hydroxy-3-quinolin-5-yloxypropyl)piperazin-1-yl]-2,2-diphenylethanone Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.C=1C=CC2=NC=CC=C2C=1OCC(O)CN(CC1)CCN1C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC2=NC=CC=C2C=1OCC(O)CN(CC1)CCN1C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 ZGMJYTYLTJFNCS-VQYXCCSOSA-N 0.000 description 1
ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
DKXKUILKIAMLSD-UHFFFAOYSA-N 1-(3-chloropropoxy)-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1OCCCCl DKXKUILKIAMLSD-UHFFFAOYSA-N 0.000 description 1
VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
AWBOSXFRPFZLOP-UHFFFAOYSA-N 2,1,3-benzoxadiazole Chemical compound C1=CC=CC2=NON=C21 AWBOSXFRPFZLOP-UHFFFAOYSA-N 0.000 description 1
ZKODPGZNBMIZFX-UHFFFAOYSA-N 2-(2-bromoethyl)oxirane Chemical compound BrCCC1CO1 ZKODPGZNBMIZFX-UHFFFAOYSA-N 0.000 description 1
NKWKILGNDJEIOC-UHFFFAOYSA-N 2-(2-chloroethyl)oxirane Chemical compound ClCCC1CO1 NKWKILGNDJEIOC-UHFFFAOYSA-N 0.000 description 1
PNKIAICRRFHSBQ-UHFFFAOYSA-N 2-(bromomethyl)-3-methyloxirane Chemical compound CC1OC1CBr PNKIAICRRFHSBQ-UHFFFAOYSA-N 0.000 description 1
MMTOSBCMFDNOIY-UHFFFAOYSA-N 2-(chloromethyl)-3-methyloxirane Chemical compound CC1OC1CCl MMTOSBCMFDNOIY-UHFFFAOYSA-N 0.000 description 1
PVNTURWWDZNXTK-UHFFFAOYSA-N 2-(difluoromethoxy)phenol Chemical compound OC1=CC=CC=C1OC(F)F PVNTURWWDZNXTK-UHFFFAOYSA-N 0.000 description 1
IYFFPRFMOMGBGB-UHFFFAOYSA-N 2-[(2-chlorophenoxy)methyl]oxirane Chemical compound ClC1=CC=CC=C1OCC1OC1 IYFFPRFMOMGBGB-UHFFFAOYSA-N 0.000 description 1
HCSMVOFDAVUSSV-UHFFFAOYSA-N 2-butoxyquinoline Chemical compound C1=CC=CC2=NC(OCCCC)=CC=C21 HCSMVOFDAVUSSV-UHFFFAOYSA-N 0.000 description 1
ISPYQTSUDJAMAB-UHFFFAOYSA-N 2-chlorophenol Chemical compound OC1=CC=CC=C1Cl ISPYQTSUDJAMAB-UHFFFAOYSA-N 0.000 description 1
BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical group CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 1
125000004810 2-methylpropylene group Chemical group [H]C([H])([H])C([H])(C([H])([H])[*:2])C([H])([H])[*:1] 0.000 description 1
MLMQPDHYNJCQAO-UHFFFAOYSA-N 3,3-dimethylbutyric acid Chemical compound CC(C)(C)CC(O)=O MLMQPDHYNJCQAO-UHFFFAOYSA-N 0.000 description 1
AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 description 1
ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
BMVWCPGVLSILMU-UHFFFAOYSA-N 5,6-dihydrodibenzo[2,1-b:2',1'-f][7]annulen-11-one Chemical group C1CC2=CC=CC=C2C(=O)C2=CC=CC=C21 BMVWCPGVLSILMU-UHFFFAOYSA-N 0.000 description 1
MMRYHBTWIHLITG-SECBINFHSA-N 5-[[(2r)-oxiran-2-yl]methoxy]quinoline Chemical compound C=1C=CC2=NC=CC=C2C=1OC[C@H]1CO1 MMRYHBTWIHLITG-SECBINFHSA-N 0.000 description 1
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
206010053398 Clonic convulsion Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
KGWDUNBJIMUFAP-KVVVOXFISA-N Ethanolamine Oleate Chemical compound NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O KGWDUNBJIMUFAP-KVVVOXFISA-N 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
241000282412 Homo Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
231100000002 MTT assay Toxicity 0.000 description 1
238000000134 MTT assay Methods 0.000 description 1
241001529936 Murinae Species 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
WVTGEXAIVZDLCR-UHFFFAOYSA-N Vindoline Natural products CC1C2CN3CCCC14CCC5Nc6ccccc6C25C34 WVTGEXAIVZDLCR-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000003432 anti-folate effect Effects 0.000 description 1
229940127074 antifolate Drugs 0.000 description 1
229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
150000008209 arabinosides Chemical class 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
230000008901 benefit Effects 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
VCLJKHAVJDVQNE-UHFFFAOYSA-N bicyclo[5.1.0]octa-1(8),2,4,6-tetraene Chemical compound C1=CC=CC=C2C=C21 VCLJKHAVJDVQNE-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000005422 blasting Methods 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
235000014121 butter Nutrition 0.000 description 1
230000009460 calcium influx Effects 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
230000003185 calcium uptake Effects 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
229960005243 carmustine Drugs 0.000 description 1
GKWYINOZGDHWRA-UHFFFAOYSA-N catharanthine Natural products C1C(CC)(O)CC(CC2C(=O)OC)CN1CCC1=C2NC2=CC=CC=C12 GKWYINOZGDHWRA-UHFFFAOYSA-N 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000006364 cellular survival Effects 0.000 description 1
150000001793 charged compounds Chemical class 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Substances ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
229960001338 colchicine Drugs 0.000 description 1
238000007398 colorimetric assay Methods 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
229940125846 compound 25 Drugs 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
229960003901 dacarbazine Drugs 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000001784 detoxification Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
238000009510 drug design Methods 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
238000007877 drug screening Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
229940031124 ethanolamine oleate Drugs 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
239000004052 folic acid antagonist Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
229940097043 glucuronic acid Drugs 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
235000021552 granulated sugar Nutrition 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
230000026030 halogenation Effects 0.000 description 1
238000005658 halogenation reaction Methods 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
150000002466 imines Chemical class 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
238000011396 initial chemotherapy Methods 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
229960002247 lomustine Drugs 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
QQHSHLKOWBDOFC-UHFFFAOYSA-N methyl 2,2,2-tribromoacetate Chemical compound COC(=O)C(Br)(Br)Br QQHSHLKOWBDOFC-UHFFFAOYSA-N 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
125000004170 methylsulfonyl group Chemical class [H]C([H])([H])S(*)(=O)=O 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000004533 oil dispersion Substances 0.000 description 1
229940100692 oral suspension Drugs 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
239000002245 particle Substances 0.000 description 1
125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
WEYVCQFUGFRXOM-UHFFFAOYSA-N perazine Chemical compound C1CN(C)CCN1CCCN1C2=CC=CC=C2SC2=CC=CC=C21 WEYVCQFUGFRXOM-UHFFFAOYSA-N 0.000 description 1
229960002195 perazine Drugs 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
XKZXGTOMPVMYOS-UHFFFAOYSA-N piperazine;propane Chemical compound CCC.C1CNCCN1 XKZXGTOMPVMYOS-UHFFFAOYSA-N 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
239000003495 polar organic solvent Substances 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
229960000624 procarbazine Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
239000008213 purified water Substances 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
239000000376 reactant Substances 0.000 description 1
238000010992 reflux Methods 0.000 description 1
BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
229960003147 reserpine Drugs 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
238000012552 review Methods 0.000 description 1
MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000007974 sodium acetate buffer Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
IZJLVZAQCUZJQO-UHFFFAOYSA-M sodium;2,2-dichloro-2-fluoroacetate Chemical compound [Na+].[O-]C(=O)C(F)(Cl)Cl IZJLVZAQCUZJQO-UHFFFAOYSA-M 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
229950006315 spirogermanium Drugs 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
238000010998 test method Methods 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
125000002088 tosyl group Chemical class [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
229940117013 triethanolamine oleate Drugs 0.000 description 1
ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
208000037965 uterine sarcoma Diseases 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
CXBGOBGJHGGWIE-IYJDUVQVSA-N vindoline Chemical compound CN([C@H]1[C@](O)([C@@H]2OC(C)=O)C(=O)OC)C3=CC(OC)=CC=C3[C@]11CCN3CC=C[C@]2(CC)[C@@H]13 CXBGOBGJHGGWIE-IYJDUVQVSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Tropical Medicine & Parasitology (AREA)
Addiction (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Quinoline Compounds (AREA)
Pyridine Compounds (AREA)
Fats And Perfumes (AREA)

FI954979A 1993-04-19 1995-10-18 Menetelmä kemoherkistävinä aineina käyttökelpoisten 10,11-metanodibentsosuberaanijohdannaisten valmistamiseksi FI111161B (fi)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US4906593		1993-04-19
US08/049,065 US5643909A (en)	1993-04-19	1993-04-19	10,11-Methanodibenzosuberane derivatives
US9404215		1994-04-13
PCT/US1994/004215 WO1994024107A1 (fr)	1993-04-19	1994-04-13	Derives de 10,11-methanodibenzosuberane utilises comme agents de chimiosensibilisation

Publications (3)

Publication Number	Publication Date
FI954979A7 FI954979A7 (fi)	1995-10-18
FI954979A0 FI954979A0 (fi)	1995-10-18
FI111161B true FI111161B (fi)	2003-06-13

Family

ID=21957890

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI954979A FI111161B (fi)	1993-04-19	1995-10-18	Menetelmä kemoherkistävinä aineina käyttökelpoisten 10,11-metanodibentsosuberaanijohdannaisten valmistamiseksi

Country Status (21)

Country	Link
US (5)	US5643909A (fr)
EP (2)	EP0695293B1 (fr)
JP (1)	JP3020607B2 (fr)
KR (1)	KR100248591B1 (fr)
CN (2)	CN1045204C (fr)
AT (1)	ATE172194T1 (fr)
AU (1)	AU678470B2 (fr)
BR (1)	BR9405965A (fr)
CA (1)	CA2160881C (fr)
CZ (1)	CZ287273B6 (fr)
DE (1)	DE69413958T2 (fr)
DK (1)	DK0695293T3 (fr)
ES (1)	ES2121603T3 (fr)
FI (1)	FI111161B (fr)
HU (2)	HU227824B1 (fr)
NO (1)	NO313284B1 (fr)
NZ (1)	NZ265547A (fr)
PL (1)	PL183375B1 (fr)
RU (1)	RU2167154C2 (fr)
UA (1)	UA42720C2 (fr)
WO (1)	WO1994024107A1 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5643909A (en) *	1993-04-19	1997-07-01	Syntex (U.S.A.) Inc.	10,11-Methanodibenzosuberane derivatives
US5661152A (en) *	1993-10-15	1997-08-26	Schering Corporation	Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6365588B1 (en)	1993-10-15	2002-04-02	Schering Corporation	Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6075025A (en)	1993-10-15	2000-06-13	Schering Corporation	Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5721236A (en) *	1993-10-15	1998-02-24	Schering Corporation	Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5719148A (en) *	1993-10-15	1998-02-17	Schering Corporation	Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5567592A (en) *	1994-02-02	1996-10-22	Regents Of The University Of California	Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
EP0777472A2 (fr)	1994-08-31	1997-06-11	Eli Lilly And Company	Procedes d'identification et de traitement de tumeurs resistantes
US5684013A (en) *	1995-03-24	1997-11-04	Schering Corporation	Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5700806A (en) *	1995-03-24	1997-12-23	Schering Corporation	Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5801175A (en)	1995-04-07	1998-09-01	Schering Corporation	Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5891872A (en) *	1995-04-07	1999-04-06	Schering Corporation	Tricyclic compounds
US5712280A (en) *	1995-04-07	1998-01-27	Schering Corporation	Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5874442A (en) *	1995-12-22	1999-02-23	Schering-Plough Corporation	Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
ES2151277T3 (es) *	1996-05-22	2000-12-16	Protarga Inc	Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
US5795909A (en)	1996-05-22	1998-08-18	Neuromedica, Inc.	DHA-pharmaceutical agent conjugates of taxanes
US5919815A (en) *	1996-05-22	1999-07-06	Neuromedica, Inc.	Taxane compounds and compositions
AU3486297A (en) *	1996-06-17	1998-01-07	Eli Lilly And Company	Drug resistance and multidrug resistance modulators
IL130055A0 (en) *	1996-11-22	2000-02-29	Lilly Co Eli	Drug resistance and multidrug resistance modulators
US6268500B1 (en)	1997-01-31	2001-07-31	Eli Lilly And Company	Separation of 5-nitroquinoline and 8-nitroquinoline
US5776939A (en) *	1997-06-12	1998-07-07	Eli Lilly And Company	Drug resistance and multidrug resistance modulators
US6635281B2 (en)	1998-12-23	2003-10-21	Alza Corporation	Gastric retaining oral liquid dosage form
US6342249B1 (en)	1998-12-23	2002-01-29	Alza Corporation	Controlled release liquid active agent formulation dosage forms
US7235583B1 (en)	1999-03-09	2007-06-26	Luitpold Pharmaceuticals, Inc.,	Fatty acid-anticancer conjugates and uses thereof
CA2373484C (fr)	1999-05-19	2009-01-20	Noboru Kaneko	Utilisation de derives 1,4-benzothiazepine en tant que medicaments contre la tolerance cancerostatique
TWI267511B (en)	1999-06-03	2006-12-01	Lilly Co Eli	Process for preparing 10,11-methanobenzosuberane derivatives
DE60014386T2 (de)	1999-06-03	2005-10-13	Eli Lilly And Co., Indianapolis	Verfahren zur herstellung von 10,11methanodibenzosuberanderivaten
WO2001010387A2 (fr) *	1999-08-09	2001-02-15	Vanderbilt University	Utilisation de modulateurs de p-glycoproteine dans un traitement antiviral
US6426342B2 (en) *	1999-08-16	2002-07-30	Revaax Pharmaceuticals, Llc	Use of β-lactamase inhibitors as neuroprotectants
ATE518540T1 (de) *	1999-08-16	2011-08-15	Revaax Pharmaceuticals Llc	Beta-lactam verbindung enthaltende neurotherapeutische zusammensetzung
WO2002005818A2 (fr) *	2000-07-18	2002-01-24	Eli Lilly And Company	Methode d'utilisation de modulateurs de la resistance multiple aux medicaments
US7342016B2 (en)	2000-08-30	2008-03-11	Schering Corporation	Farnesyl protein transferase inhibitors as antitumor agents
US6376514B1 (en)	2000-10-17	2002-04-23	The Procter & Gamble Co.	Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6693099B2 (en)	2000-10-17	2004-02-17	The Procter & Gamble Company	Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
DE60202944T2 (de) *	2001-04-25	2006-03-23	Eli Lilly And Co., Indianapolis	Neue salze und kristalline formen von (2r)-anti-5-3-(4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl)-2-hydroxypropoxy quinolin
US20050232995A1 (en)	2002-07-29	2005-10-20	Yam Nyomi V	Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20050208132A1 (en) *	2002-07-29	2005-09-22	Gayatri Sathyan	Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20050152967A1 (en) *	2003-03-28	2005-07-14	Pfab, Lp	Dynamic variable release
AU2004291081A1 (en) *	2003-11-14	2005-06-02	Alza Corporation	Controlled release of topirimate in liquid dosage forms
WO2006023286A2 (fr) *	2004-08-19	2006-03-02	Alza Corporation	Formes posologiques renfermant une formulation d'agent actif nanoparticulaire a liberation retardee et procedes
KR20080005429A (ko) *	2005-04-19	2008-01-11	알자 코포레이션	트라마돌 및 가바펜틴을 포함하는 물질의 배합물
US20070010486A1 (en) *	2005-07-06	2007-01-11	Jeff Schwegman	Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070009531A1 (en) *	2005-07-06	2007-01-11	Branimir Sikic	Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
US20070009535A1 (en) *	2005-07-06	2007-01-11	Branimir Sikic	Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism
US20070010478A1 (en) *	2005-07-06	2007-01-11	Branimir Sikic	Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US20070009534A1 (en) *	2005-07-06	2007-01-11	Branimir Sikic	Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism
AU2006269498A1 (en) *	2005-07-06	2007-01-18	Edgar, Mark	Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070009533A1 (en) *	2005-07-06	2007-01-11	Branimir Sikic	Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism
US20070010487A1 (en) *	2005-07-06	2007-01-11	Jeff Schwegman	Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010485A1 (en) *	2005-07-06	2007-01-11	Jeff Schwegman	Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
AR055099A1 (es) *	2005-07-28	2007-08-08	Alza Corp	Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
EP1933811A2 (fr) *	2005-09-30	2008-06-25	Alza Corporation	Formes posologiques a liberation regulee a bandelettes renfermant des preparations d'agents actifs nanoparticulaires
PL116330U1 (en) *	2005-10-31	2007-04-02	Alza Corp	Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
TW200908957A (en) *	2007-06-15	2009-03-01	Xenoport Inc	Use of prodrugs of GABA analogs, antispasticity agents, and prodrugs of GABAB receptor agonists for treating spasticity
CN102413814A (zh) *	2009-04-29	2012-04-11	瑞恩药品公司	用于神经保护和治疗神经变性病症的克拉维酸类物质制剂
US9617230B2 (en)	2014-12-22	2017-04-11	Farmington Pharma Development	Creatine prodrugs, compositions and methods of use thereof
US11240349B2 (en)	2014-12-31	2022-02-01	Ebay Inc.	Multimodal content recognition and contextual advertising and content delivery
US11332438B2 (en)	2017-12-01	2022-05-17	Ultragenyx Pharmaceutical Inc.	Creatine prodrugs, compositions and methods of use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3133925A (en) *	1960-12-22	1964-05-19	Searle & Co	Ether derivatives of n-benzhydryl-n'-dihydroxypropylpiperazines and homopiperazines
GB1317034A (en) *	1970-11-06	1973-05-16	Pfizer Ltd	1-2-hydroxy-3-phenoxy- or -phenylthiopropyl-piperazine derivatives
IT1037099B (it) *	1975-01-24	1979-11-10	Erba Carlo Spa	N derivati tricilici dell azetidina
US4015003A (en) *	1975-09-26	1977-03-29	E. I. Du Pont De Nemours And Company	Antidepressant 1,1a,6,10b-tetrahydrodibenzo[a,e]-cyclopropa-[c]-cyclohepten-6-substituted oximes
JPS5278882A (en) *	1975-12-24	1977-07-02	Sumitomo Chem Co Ltd	Synthesis of novel morpholine derivatives
JPS5278881A (en) *	1975-12-24	1977-07-02	Sumitomo Chem Co Ltd	Synthesis of novel morpholine derivativs
JPS5278884A (en) *	1975-12-25	1977-07-02	Sumitomo Chem Co Ltd	Synthesis of novel morpholine derivatives
JPS52105184A (en) *	1976-02-26	1977-09-03	Sumitomo Chem Co Ltd	Novel morpholine derivatives
GB2163150B (en) *	1984-07-19	1988-05-25	Sandoz Ltd	3-aminopropoxyaryl derivatives
JPS6147466A (ja) *	1984-08-10	1986-03-07	Dainippon Pharmaceut Co Ltd	アミン誘導体
DE3600390A1 (de) *	1986-01-09	1987-07-16	Hoechst Ag	Diarylalkyl-substituierte alkylamine, verfahren zu ihrer herstellung, ihre verwendung sowie sie enthaltende arzneimittel
JPH0278884A (ja) *	1987-11-06	1990-03-19	Sanyo Electric Co Ltd	断熱箱体の内箱
JPH0278881A (ja) *	1988-09-13	1990-03-19	Waaku:Kk	真空冷却装置
JPH0278882A (ja) *	1988-09-14	1990-03-19	Toshiba Corp	冷蔵庫
CA1340821C (fr) *	1988-10-06	1999-11-16	Nobuyuki Fukazawa	Composes heterocycliques, ainsi que des adjuvants de produits anti-cancereux les comprenant
JPH02105184A (ja) *	1988-10-14	1990-04-17	Canon Inc	現像装置
JP2781073B2 (ja) *	1991-02-16	1998-07-30	三井化学株式会社	新規キノリン誘導体及びそれを有効成分として含有する制癌剤効果増強剤
JPH0525168A (ja) *	1991-07-15	1993-02-02	Kyorin Pharmaceut Co Ltd	癌細胞に対する感受性増強剤及びその製造方法
CA2074061A1 (fr) *	1991-08-26	1993-02-27	Ivo Monkovic	Benzamides, agents d'inversion de la resistance multiple aux anti-cancereux
JP3076672B2 (ja) *	1992-06-18	2000-08-14	三井化学株式会社	キノリン誘導体のフマル酸塩
US5643909A (en) *	1993-04-19	1997-07-01	Syntex (U.S.A.) Inc.	10,11-Methanodibenzosuberane derivatives

1993
- 1993-04-19 US US08/049,065 patent/US5643909A/en not_active Expired - Lifetime
1994
- 1994-04-13 KR KR1019950704552A patent/KR100248591B1/ko not_active Expired - Lifetime
- 1994-04-13 NZ NZ265547A patent/NZ265547A/en not_active IP Right Cessation
- 1994-04-13 DK DK94914200T patent/DK0695293T3/da active
- 1994-04-13 EP EP94914200A patent/EP0695293B1/fr not_active Expired - Lifetime
- 1994-04-13 DE DE69413958T patent/DE69413958T2/de not_active Expired - Lifetime
- 1994-04-13 HU HU9503004A patent/HU227824B1/hu unknown
- 1994-04-13 RU RU95120598/04A patent/RU2167154C2/ru active
- 1994-04-13 PL PL94311164A patent/PL183375B1/pl unknown
- 1994-04-13 CZ CZ19952724A patent/CZ287273B6/cs not_active IP Right Cessation
- 1994-04-13 WO PCT/US1994/004215 patent/WO1994024107A1/fr not_active Ceased
- 1994-04-13 CN CN94191807A patent/CN1045204C/zh not_active Expired - Lifetime
- 1994-04-13 EP EP98100510A patent/EP0866063A1/fr not_active Ceased
- 1994-04-13 AU AU66362/94A patent/AU678470B2/en not_active Expired
- 1994-04-13 BR BR9405965A patent/BR9405965A/pt not_active Application Discontinuation
- 1994-04-13 JP JP6523504A patent/JP3020607B2/ja not_active Expired - Lifetime
- 1994-04-13 AT AT94914200T patent/ATE172194T1/de active
- 1994-04-13 UA UA95114910A patent/UA42720C2/uk unknown
- 1994-04-13 ES ES94914200T patent/ES2121603T3/es not_active Expired - Lifetime
- 1994-04-13 CA CA002160881A patent/CA2160881C/fr not_active Expired - Lifetime
1995
- 1995-05-08 US US08/435,070 patent/US5654304A/en not_active Expired - Lifetime
- 1995-05-08 US US08/436,992 patent/US5889007A/en not_active Expired - Lifetime
- 1995-06-20 HU HU95P/P00274P patent/HU211682A9/hu unknown
- 1995-10-18 FI FI954979A patent/FI111161B/fi not_active IP Right Cessation
- 1995-10-18 NO NO19954161A patent/NO313284B1/no not_active IP Right Cessation
1997
- 1997-02-03 US US08/792,746 patent/US5874434A/en not_active Expired - Lifetime
1999
- 1999-01-25 US US09/236,525 patent/US6087365A/en not_active Expired - Fee Related
- 1999-04-22 CN CN99105238A patent/CN1119149C/zh not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JPH08509223A (ja)	1996-10-01
FI954979A7 (fi)	1995-10-18
HU211682A9 (en)	1995-12-28
NZ265547A (en)	1997-03-24
EP0695293B1 (fr)	1998-10-14
RU2167154C2 (ru)	2001-05-20
AU6636294A (en)	1994-11-08
CZ272495A3 (en)	1996-04-17
CN1235826A (zh)	1999-11-24
NO954161L (no)	1995-12-05
US5654304A (en)	1997-08-05
NO954161D0 (no)	1995-10-18
PL311164A1 (en)	1996-02-05
CN1045204C (zh)	1999-09-22
PL183375B1 (pl)	2002-06-28
CN1119149C (zh)	2003-08-27
HK1011981A1 (en)	1999-07-23
DK0695293T3 (da)	1999-06-23
US5889007A (en)	1999-03-30
DE69413958D1 (de)	1998-11-19
NO313284B1 (no)	2002-09-09
AU678470B2 (en)	1997-05-29
CZ287273B6 (en)	2000-10-11
DE69413958T2 (de)	1999-03-11
FI954979A0 (fi)	1995-10-18
HU227824B1 (en)	2012-03-28
EP0695293A1 (fr)	1996-02-07
UA42720C2 (uk)	2001-11-15
HUT73180A (en)	1996-06-28
EP0866063A1 (fr)	1998-09-23
US6087365A (en)	2000-07-11
CA2160881A1 (fr)	1994-10-27
US5643909A (en)	1997-07-01
BR9405965A (pt)	1996-01-30
KR100248591B1 (ko)	2000-04-01
ES2121603T3 (es)	1998-12-01
JP3020607B2 (ja)	2000-03-15
WO1994024107A1 (fr)	1994-10-27
US5874434A (en)	1999-02-23
CN1121346A (zh)	1996-04-24
CA2160881C (fr)	2000-12-12
ATE172194T1 (de)	1998-10-15
HU9503004D0 (en)	1995-12-28

Legal Events

Date	Code	Title	Description
2014-05-28	MA	Patent expired

Publication	Publication Date	Title
FI111161B (fi)	2003-06-13	Menetelmä kemoherkistävinä aineina käyttökelpoisten 10,11-metanodibentsosuberaanijohdannaisten valmistamiseksi
EP0367141B1 (fr)	1996-01-10	Dérivés de carbostyriles
US4980365A (en)	1990-12-25	N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds as analgesic and hypotensive agents
HU190902B (en)	1986-12-28	Process for preparing 1-aryl-oxy-2,3,4,5-tetrahydro-3-benzazepine derivatives and acid addition salts thereof
US5008264A (en)	1991-04-16	N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds as analgesic and hypotensive agents
US6130219A (en)	2000-10-10	Drug resistance and multidrug resistance modulators
US6187787B1 (en)	2001-02-13	Bis(9-aminoacridine) DNA intercalating agents having antitumor activity
RU2384572C2 (ru)	2010-03-20	Соли арипипразола
HK1011981B (en)	2000-03-24	10,11-methanodibenzosuberane derivatives used as chemosensitizing agents
JPH0357903B2 (fr)	1991-09-03
DK154071B (da)	1988-10-10	Analogifremgangsmaade til fremstilling af substituerede benzenderivater
EP0844244A1 (fr)	1998-05-27	Modulateurs de résistance à un ou plusieurs médicaments
GB2044260A (en)	1980-10-15	New piperidine derivatives process for their preparation and their therapeutic applications
HK1011209A (en)	1999-07-09	Drug resistance and multidrug resistance modulators
HK1002706B (en)	1998-09-11	Carbostyril derivatives
MXPA99004667A (en)	2000-04-24	Drug resistance and multidrug resistance modulators